The biopharmaceutical sector is truly a battlefield. BDRX and RADX have been soaring like a roller coaster recently, with RADX's +100% daily gain even putting the A-shares to shame. Honestly, I'm even afraid to chase the highs...
Small-cap pharma stocks are like this—when policy or trial news hits, the drama starts immediately. Unfortunately, my old bones can't take the risk anymore 😮💨
The volatility in OSCR and YCBD seems like just thematic rotation and hype, but the moat is ultimately too narrow. All I can say is, in this market, what you don't earn is what you keep.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
